SPONSOR
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Total Trials
10
Recruiting
10
Phases
Phase 1, Phase 2, Phase 1, Phase 2, Phase 2, Phase 3, Phase 3
Conditions studied: Malignant Solid TumorsAdvanced Solid TumorsAdvanced Esophageal Squamous Cell CarcinomaBiliary Tract CancerFor Prevention of Bone Events in Patients With Bone Metastases From Solid TumorsAdvanced Solid TumorLocally Advanced Resectable Rectal CancerPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Malignant Solid Tumors, Advanced Solid Tumors, Advanced Esophageal Squamous Cell Carcinoma, Biliary Tract Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
How many clinical trials has Suzhou Suncadia Biopharmaceuticals Co., Ltd. sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., of which 10 are actively recruiting participants. These trials cover conditions including Malignant Solid Tumors, Advanced Solid Tumors, Advanced Esophageal Squamous Cell Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Suzhou Suncadia Biopharmaceuticals Co., Ltd. research focus on?
Suzhou Suncadia Biopharmaceuticals Co., Ltd. clinical trials span Malignant Solid Tumors, Advanced Solid Tumors, Advanced Esophageal Squamous Cell Carcinoma, Biliary Tract Cancer, For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Suzhou Suncadia Biopharmaceuticals Co., Ltd. clinical trial?
To participate in a Suzhou Suncadia Biopharmaceuticals Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Suzhou Suncadia Biopharmaceuticals Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06737731 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
Malignant Solid Tumors
NCT06094556 Phase 1
Recruiting
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Advanced Solid Tumors
NCT07751341 Phase 2
Recruiting
A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Advanced Esophageal Squamous Cell Carcinoma
NCT06703177 Phase 1, Phase 2
Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Advanced Solid Tumors
NCT07450976 Phase 2
Recruiting
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Biliary Tract Cancer
NCT07028268 Phase 2
Recruiting
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors
NCT07298772 Phase 1, Phase 2
Recruiting
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Advanced Solid Tumor
NCT06618651 Phase 1
Recruiting
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Advanced Solid Tumors
NCT07454720 Phase 2, Phase 3
Recruiting
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Locally Advanced Resectable Rectal Cancer
NCT07111832 Phase 3
Recruiting
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology